Table 2A.

Risk factors for discontinuation of ADA due to insufficient efficacy up to 1 year and after 1 year from initiation of treatment.

Variables	Up to 1 Yr				After 1 Yr
	Univariate Analysis		Multivariate Analysis		Univariate Analysis		Multivariate Analysis
	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
Age, yrs	1.01 (0.99–1.02)	0.46	1.00 (0.98–1.02)	0.89	1.00 (0.98–1.04)	0.56	1.00 (0.95–1.03)	0.60
Sex	0.84 (0.49–1.44)	0.52	1.02 (0.48–2.17)	0.96	0.78 (0.34–1.80)	0.56	1.13 (0.33–3.86)	0.85
Disease duration, yrs	0.96 (0.93–1.01)	0.056	0.97 (0.93–1.01)	0.082	1.01 (0.98–1.04)	0.39	0.99 (0.94–1.04)	0.60
Stage	0.85 (0.66–1.08)	0.17	0.91 (0.65–1.29)	0.60	1.20 (0.76–1.90)	0.43	1.13 (0.61–2.11)	0.69
Class	1.26 (0.88–1.80)	0.21	1.20 (0.76–1.91)	0.44	1.22 (0.71–2.09)	0.47	2.03 (0.92–4.46)	0.08
Previous biologics	1.58 (1.03–2.45)	< 0.05	2.40 (1.30–4.42)	< 0.01	1.37 (0.68–2.76)	0.37	1.28 (0.49–3.37)	0.62
Prednisolone use	1.04 (0.67–1.63)	0.85	1.00 (0.55–1.82)	0.99	1.69 (0.76–3.76)	0.19	1.24 (0.47–3.26)	0.66
Methotrexate use	0.76 (0.44–1.32)	0.33	1.00 (0.47–2.15)	0.996	0.26 (0.12–0.55)	< 0.001	0.26 (0.10–0.67)	< 0.01
DAS28-CRP	1.24 (1.06–1.45)	< 0.01	1.61 (1.28–2.02)	< 0.0001	1.19 (0.90–1.57)	0.21	0.97 (0.63–1.50)	0.89

HR and 95% CI for discontinuation of ADA were estimated with Cox proportional hazards regression analysis. ADA: adalimumab; DAS28-CRP: Disease Activity Score in 28 joints based on C-reactive protein.